Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of a Booster Dose of FLUAD-H5N1
2007-000165-38Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Audenz in avian influenza (HPAI), sponsored by Novartis. Primary endpoints: Persistence of antibody titers at 17–18 months after primary immunization, Immunogenicity of one 0.5 mL IM booster dose of FLUAD-H5N1 and 1 more. Started Jul 2007; status: completed.
02
Drugs
Audenz
03
Conditions
avian influenza (HPAI)
Beyond the preview
Go deeper on 2007-000165-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000165-38.